Enzo Biochem's Clinical Lab Division Enters Exclusive Agreement with Novel Sequencing Provider MultiGEN Diagnostics

Published: Mar 15, 2010

NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

Back to news